Biotech stocks fall in January
Wednesday, 08 February, 2006
Biotechnology stocks have continued to underperform in January -- with the Intersuisse biotechnology index sliding by 0.9 per cent.
This compares with gains in January by both the All Ordinaries and the Nasdaq biotechnology index, of 3.6 per cent and 4.2 respectively.
However, Australian biotechnology stocks still outperformed the All Ordinaries and Nasdaq indices when calculated from June 2005, due to strong performance in the four months after that date.
In January, 30 companies showed price rises, 43 fell and seven stocks remained unchanged.
Gains over 20 per cent
Living Cell Technologies (ASX:LCT) - 38 per cent Biotron (ASX:BIT) - 32 per cent Cathrx (ASX:CXD) - 24 per cent Heartware (ASX:HTW) - 23 per cent Life Therapeutics (ASX:LFE) - 21 per cent
Falls over 20 per cent
Advanced Ocular Systems (formerly Regenera) (ASX:AOS) - 37 per cent Occupational & Medical Innovations (ASX:OMI) - 31 per cent Clinical Cell Culture (ASX:CCE) - 25 per cent
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
